NCT01519492View on ClinicalTrials.gov

A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Skin and Subcutaneous Tissue Bacterial InfectionsWound InfectionCutaneous AbscessBurn InfectionCellulitis
Interventions
DRUG

AFN-12520000

Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg

Trial Locations (14)

30909

SITE 017, Augusta

31406

SITE 004, Savannah

31904

SITE 002, Columbus

37232

SITE 008, Nashville

43608

SITE 011, Toledo

45267

SITE 007, Cincinnati

89109

SITE 006, Las Vegas

90620

SITE 018, Buena Park

91911

SITE 005, Chula Vista

91942

SITE 001, La Mesa

92056

SITE 016, Oceanside

08244

SITE 003, Somers Point

T6G 2B7

SITE 014, Edmonton

K7L 2V7

SITE 015, Kingston

Sponsors
All Listed Sponsors
lead

Affinium Pharmaceuticals, Ltd

INDUSTRY

NCT01519492 - A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci | Biotech Hunter | Biotech Hunter